Senores Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals received its annual disclosure from promoter Mr. Swapnil Jatinbhai Shah on behalf of the entire Promoter Group and Persons Acting in Concert (PAC). The filing confirms that no new share encumbrances (pledges or charges) were created by the promoter group during the Financial Year ending March 31, 2026, beyond any already disclosed to the stock exchanges during the year. This is a mandatory annual compliance filing under SEBI's substantial acquisition regulations. The disclosure was signed by both the Company Secretary (Vinay Kumar Mishra) and the Promoter (Swapnil Jatinbhai Shah) and copies were sent to BSE (Scrip Code: 544319) and NSE (Symbol: SENORES), as well as the Audit Committee Chairman.
The disclosure is neutral-to-slightly positive for investors as it indicates the promoter group has not taken on additional debt backed by company shares, reducing dilution or forced-sale risk. No new pledges were placed on promoter shares during the year.